This initiative, partly funded by the National Institutes of Health and The Mark Foundation, was carried out in collaboration with the Society for Immunotherapy of Cancer (SITC) and the International Neoadjuvant Melanoma Consortium (INMC). The updated guidelines, recently published in the prestigious journal Annals of Oncology, represent the first pan-tumor consensus designed to harmonize pathological assessment after neoadjuvant therapy. By refining and building upon immune-related criteria initially established for lung cancer in 2018 and expanded in 2020, the consortium ensures the guidelines incorporate half a decade of clinical application, feedback, and new reproducibility data.

The core innovation lies in the introduction of standardized parameters to assess residual viable tumor (RVT), necrosis, and regression—histological markers of treatment response that include inflammation and the signature traits of wound healing within tumor tissue. This comprehensive approach supersedes multiple tumor-specific systems, which previously complicated clinical interpretation and trial comparisons. With neoadjuvant therapies rapidly expanding across cancer types, including immunotherapy regimens targeting checkpoints such as PD-1, establishing a reliable, reproducible framework for pathological response is indispensable for clinical decision-making and research.

Julie Stein Deutsch, M.D., an assistant professor at Johns Hopkins and lead author of the study, underscores the clinical significance of this unified approach. She highlights that pathologic response is becoming a cornerstone in predicting long-term patient survival and an increasingly important endpoint in clinical trials. The disparity in scoring systems across tumor types has hindered the ability to draw consistent conclusions from diverse studies. The new guidelines offer a common language, greatly facilitating data consolidation, cross-trial comparison, and regulatory evaluation.

The genesis of these harmonized guidelines traces back to meticulous research analyzing approximately 500 tumor specimens treated with anti-PD-1 immunotherapies, either as monotherapy or combined with chemotherapy or targeted agents. Remarkably, the researchers observed analogous histopathological patterns of tumor regression irrespective of cancer origin. This uniformity signaled a pressing need to consolidate scoring criteria within a single, universally applicable framework to reduce confusion and improve reproducibility.

Janis Taube, M.D., senior author and director of dermatopathology at Johns Hopkins, elaborates on the practical advantages of the system. Given that most practicing pathologists are generalists rather than tumor-specific experts, navigating a patchwork of scoring guidelines is inefficient and prone to inconsistency. The newly proposed pan-tumor system not only streamlines workflow but also matches or outperforms existing tumor-specific methods in predicting patient survival outcomes, reinforcing its potential for broad adoption.

A hallmark feature of the updated guidelines is their demonstrated reproducibility across international, multi-institutional pathology teams. In a landmark study involving 14 pathologists, a brief standardized training enabled consistent scoring of residual viable tumor, necrosis, and regression across a range of solid tumor types and anatomical sites. This reproducibility extended to assessments of both surgical resection specimens and biopsy samples, confirming the system’s robustness and versatility. The findings were presented at the 2024 American Society of Clinical Oncology annual meeting, affirming the approach’s readiness for widespread clinical implementation.

The harmonized criteria bear a functional resemblance to the Response Evaluation Criteria in Solid Tumors (RECIST), a well-established method for radiographic tumor assessment used globally. This parallel allows clinicians and researchers to integrate pathological and imaging data coherently, thereby enhancing the precision of treatment response evaluations. The ability to standardize data collection is especially critical as neoadjuvant and perioperative therapies—those given before and after surgery—become standard across an expanding array of cancers.

Central to this initiative is the emphasis on reproducibility as a prerequisite for clinical utility. Dr. Deutsch emphasizes that treatment decisions and clinical trials depend on different pathologists arriving at comparable scores for identical specimens. To facilitate this, the research team has developed comprehensive training materials designed to ensure consistent application of the guidelines. The Society for Immunotherapy of Cancer is collaborating with the Johns Hopkins researchers to disseminate these resources widely, ensuring global access to standardized protocols.

The consortium anticipates that as long-term survival data from patients treated under this new scoring paradigm accumulate, further refinement of clinically relevant thresholds for residual viable tumor will become possible. These thresholds will be tailored for specific tumor types to enhance prognostic accuracy and guide therapeutic choices more precisely. This evolving framework thus represents a dynamic tool, adaptable to emerging clinical evidence and therapeutic advances.

This groundbreaking effort involves contributions from an extensive network of researchers, including experts in dermatology, pathology, oncology, immunotherapy, and bioinformatics. The team integrates expertise from institutes worldwide, supported by grants and funds from renowned organizations, including the Mark Foundation for Cancer Research, Bloomberg~Kimmel Institute, National Institutes of Health, and several international cancer research councils.

Importantly, the researchers maintain transparency regarding potential conflicts of interest, disclosing consultancy roles, research funding, and patents related to predictive methodologies in pathology. Such disclosures affirm the commitment to ethical standards, ensuring that the development and application of these guidelines are conducted with scientific integrity.

In summation, this unified, pan-tumor pathological evaluation framework marks a pivotal step toward improving the precision and consistency of neoadjuvant therapy response assessments. With validated reproducibility and broad applicability across multiple solid tumor types, the guidelines are set to revolutionize clinical cancer care and translational research. By harmonizing pathologic parameters akin to radiographic standards, the framework provides a robust foundation to accelerate oncologic innovation and optimize patient outcomes worldwide.

Subject of Research: Pathological assessment standardization of tumor response to neoadjuvant therapy across solid tumor types
Article Title: Updated Consensus Guidelines and Reproducibility Study for Pan-Tumor Pathologic Assessment of Neoadjuvant Therapy Response
News Publication Date: November 4, 2025
Web References: https://www.annalsofoncology.org/article/S0923-7534(25)04965-8/fulltext, https://www.annalsofoncology.org/article/S0923-7534(26)00038-4/fulltext
Keywords: Cancer risk, Cancer genetics, Neoadjuvant therapy, Residual viable tumor, Tumor regression, Pathologic response, Immunotherapy, PD-1 inhibitors, Pan-tumor assessment, Reproducibility, Clinical trial endpoints, Oncology

At the heart of this exploration lies a clear recognition of the challenges associated with ovarian cancer. Traditionally characterized by subtle initial symptoms, the disease often goes unnoticed until it reaches advanced stages, severely complicating treatment options and diminishing survival rates. Recognizing these challenges, researchers are turning to AI and ML to develop tools that can identify patterns and biomarkers indicative of early-stage ovarian cancer, thus facilitating earlier and more accurate diagnoses.

Machine learning algorithms, in particular, have shown remarkable promise in analyzing complex datasets, which can include patient medical histories, genetic information, and even imaging data. By training these algorithms on vast amounts of existing data, researchers can create predictive models that identify high-risk individuals and signal early cellular changes associated with tumor development. Such advancements could mean the difference between a successful early intervention and a late diagnosis leading to dire consequences.

In the treatment paradigm, AI is already making waves by personalizing therapeutic strategies based on individual patient profiles. By integrating data from clinical trials, treatment outcomes, and genetic tests, AI can aid oncologists in selecting the most effective treatment regimens tailored to specific tumor characteristics and patient responses. This level of customization not only enhances the efficacy of treatment but also minimizes adverse effects, leading to a better quality of life for patients battling ovarian cancer.

Moreover, prevention strategies are evolving with the integration of AI and ML technologies. Predictive analytics can provide insights into lifestyle factors, family history, and genetic predispositions that signal a higher risk of ovarian cancer. With this knowledge, individuals can be empowered to make informed lifestyle choices or undergo regular screenings to catch any developments early. This proactive approach to prevention signifies a cultural shift in cancer care, moving from reactive treatment to preventative care.

Additionally, AI is redefining the role of telemedicine in the management of ovarian cancer. With the ongoing global transition toward digital health solutions, AI can play an integral role in remote monitoring and consultation. Patients can receive regular check-ups and post-treatment surveillance via virtual platforms, supported by AI-driven analyses that can alert healthcare providers to any concerning changes in patient health or tumor markers. This not only enhances accessibility for patients in remote areas but also ensures that care is continuous and responsive.

The synergy between AI, ML, and genomic research is particularly noteworthy. As we dive deeper into the genetic underpinnings of ovarian cancer, these technologies can assist in identifying mutations and abnormalities that traditional methods may overlook. By leveraging AI to interpret genomic data, researchers can contribute to the development of targeted therapies that directly address the molecular drivers of tumors, potentially leading to groundbreaking advancements in treatment protocols.

Furthermore, education and training in using AI tools will be essential for healthcare professionals. As these technologies become more integrated into healthcare systems, the need for trained personnel who can effectively leverage AI for diagnostic and therapeutic purposes will be critical. Educational programs need to adapt to include AI and computational methods in the curriculum to prepare the next generation of oncologists and researchers to work efficiently with these nascent technologies.

In parallel, ethical considerations regarding the use of AI in healthcare remain paramount. Issues surrounding data privacy, algorithmic bias, and the transparency of AI-driven recommendations must be addressed thoroughly. Engaging in discussions about ethical AI use will be essential for building trust among patients and healthcare providers. Ensuring fairness and equity in AI applications will help foster a healthcare landscape where technological innovations are accessible to diverse populations.

Caution is also warranted when considering the limitations of AI and ML in the context of ovarian cancer. Although the technologies offer promising solutions, their effectiveness hinges on the quality and diversity of the data used for training algorithms. Comprehensive datasets are essential for developing robust models that can generalize well to various patient demographics. In this regard, ongoing collaboration between clinical researchers, data scientists, and oncologists will be crucial in overcoming existing barriers and ensuring broad applicability.

Simultaneously, investment in research initiatives focusing on the development and refinement of AI applications in oncology must be a priority. Funding for multi-disciplinary projects that combine insights from genomics, medicine, computer science, and ethics will advance our understanding and implementation of AI in tackling ovarian cancer. Collaborative efforts extending beyond institutional boundaries, including partnerships with technology companies, could drastically accelerate the pace of innovation in this area.

As the landscape of ovarian cancer detection, treatment, and prevention evolves under the influence of artificial intelligence and machine learning, patients stand to benefit significantly from these advancements. With enhanced diagnostic capabilities, personalized treatment regimens, and proactive prevention strategies, the prognosis for ovarian cancer can be transformed. The promise of AI in this domain highlights an exciting future where technology intersects with human health in meaningful ways, paving the way for breakthroughs that could save lives.

In summary, artificial intelligence and machine learning are poised to become cornerstone tools in the fight against ovarian cancer. By enhancing detection methods, personalizing treatment approaches, and promoting proactive prevention, these technologies are creating a new paradigm of care. Continued research and development in this field are crucial, underscoring the need for a concerted effort from all stakeholders involved in cancer care. The journey ahead is ripe with potential, as we work towards harnessing AI’s capabilities to combat one of the most challenging cancers faced by women today.

Subject of Research: Artificial intelligence (AI) and machine learning (ML) applications in ovarian cancer detection, treatment, and prevention.

Article Title: Artificial intelligence (AI) and machine learning (ML) in ovarian cancer: transforming detection, treatment, and prevention.

Article References:

Singh, M., Betgeri, S.N. & Kakar, S.S. Artificial intelligence (AI) and machine learning (ML) in ovarian cancer: transforming detection, treatment, and prevention.
J Ovarian Res (2026). https://doi.org/10.1186/s13048-026-01979-1

Image Credits: AI Generated

DOI:

Keywords: ovarian cancer, artificial intelligence, machine learning, early detection, personalized treatment, cancer prevention, telemedicine, ethical considerations.

The genesis of CCII marked a pivotal moment in cancer research, integrating cutting-edge immunological science with clinical insights to translate laboratory discoveries into viable therapies. This multidisciplinary center has notably doubled its faculty in immune-oncology from a modest ten to a dynamic twenty, creating a fertile environment that nurtures collaboration and accelerates translational research. This academic vigor directly complements the clinical prowess of the UofL Health – Brown Cancer Center, whose extensive trial programs are integral to advancing novel immunotherapies.

The essence of the CCII’s mission is underscored by the seamless bridging of fundamental immunology with clinical application. Utilizing innovative technologies such as the CyTOF instrument and Hyperion Imaging Mass Cytometry housed within their Functional Immunomics Core, researchers are able to dissect the tumor microenvironment with high-dimensional precision. These platforms provide unprecedented insights into immune cell phenotypes and their spatial distribution, fostering the development of therapies that precisely target cancer cells while sparing healthy tissue.

A particularly compelling aspect of the CCII’s work involves the strategic investigation into immune checkpoint inhibitor resistance, one of the foremost challenges in immunotherapy. By elucidating the cellular and molecular mechanisms that enable certain tumors to evade immune detection, researchers aim to design next-generation interventions that can overcome therapeutic resistance, thereby improving response rates in refractory cancers such as non-small cell lung cancer.

Clinical translation of CCII’s scientific discoveries finds a robust partner in the Brown Cancer Center, recognized nationally for its pioneering cellular therapies. Notably, the center has been a leader in tumor-infiltrating lymphocytes (TILs) therapy, a personalized treatment modality that expands a patient’s own T cells to target metastatic melanoma. This innovative therapy, after successive clinical trials and rigorous validation, attained FDA approval in 2024, signifying a watershed moment that cements the collaboration’s impact on patient survival and quality of life.

The clinical narrative is brought to life by patients like Julie Reynolds, whose journey through metastatic melanoma was transformed by the first commercial application of FDA-approved TILs therapy. Her case epitomizes the life-saving potential of translational research, where laboratory bench discoveries evolve into tangible clinical solutions, affording patients renewed hope and extended longevity.

Central to the CCII’s vision is the dedicated investment in nurturing the careers of emerging scientists who will drive the future of cancer immunotherapy. The NIH CoBRE funding framework supports junior investigators through comprehensive mentorship and access to advanced research infrastructures, facilitating their transition to independent researchers. The success of this strategy is evident, with all four initial CCII young investigators securing substantial federal funding, underscoring a vibrant pipeline of innovative research.

Noteworthy among the early career scientists is Kavitha Yaddanapudi, whose investigations into mechanisms of treatment resistance and immune profiling have directly enriched the clinical protocols at Brown Cancer Center. Her progression from mentee to mentor exemplifies the center’s ethos of building a collaborative, thriving scientific community committed to overcoming cancer.

Parallel support is extended to promising investigators like Joseph Chen, Sharmila Nair, and Jian Zheng, each leveraging CCII’s resources to develop nuanced understanding of tumor immunobiology. Their projects are instrumental in unveiling novel immune modulatory pathways and therapeutic targets, setting the stage for next-generation immunotherapies.

The Functional Immunomics Core serves as the technological backbone of the CCII, enabling comprehensive immune monitoring through high-parameter cytometry and imaging. This core facility not only enhances the quality and scope of CCII’s research but also empowers investigators across the university to pursue interdisciplinary cancer studies, catalyzing a multiplier effect in scientific discovery and innovation.

Looking forward, an exciting advancement is the planned integration of a tumor organoid fragment culture platform within CCII. This sophisticated ex vivo system authentically mimics the human tumor microenvironment, allowing precise evaluation of immunotherapeutic agents and facilitating personalized medicine approaches. By replicating the complex interactions between cancer cells and the immune milieu, tumor organoids represent a critical step towards customized treatment regimens with higher efficacy and reduced toxicity.

This expansive program at the University of Louisville epitomizes the aspirational vision of modern cancer research—melding rigorous basic science with compassionate clinical application to redefine patient outcomes. The sustained NIH funding will not only fuel scientific innovation but also fortify the infrastructure for training transformative cancer immunologists and clinicians, ensuring that advancements in cancer immunotherapy continue to evolve and reach patients locally, nationally, and worldwide.

Subject of Research: Cancer immunotherapy, immune-oncology research, tumor-infiltrating lymphocytes (TILs) therapy, immune checkpoint inhibitor resistance, translational cancer research
Article Title: University of Louisville Advances Cancer Immunotherapy with $11.5 Million NIH Grant to Propel Translational Research and Training
News Publication Date: Not specified
Web References:
– https://news.louisville.edu/news/uofl-receives-115-million-advance-cancer-immunotherapies
– https://uoflhealth.org/locations/brown-cancer-center/
– https://uoflhealth.org/news/brown-cancer-center-clinical-trial-leads-to-fda-approval-of-game-changing-cancer-treatment/
References: Not specified
Image Credits: University of Louisville
Keywords: Cancer immunotherapy, Immunology, Medical treatments, Cancer

WINSTON-SALEM, N.C., Oct. 20, 2025 —  A new study led by researchers at Wake Forest University School of Medicine, in collaboration with the University of North Carolina at Chapel Hill and MD Anderson Cancer Center, has found that a direct-to-patient digital health program can significantly increase lung cancer screening rates among people at high risk. 

The findings appear online today in JAMA. 

Lung cancer is the leading cause of cancer death worldwide, but early detection through screening can improve outcomes and save lives. Despite this, less than 20% of eligible Americans are screened for lung cancer each year. Barriers include lack of awareness, confusion about guidelines and limited time for shared decision-making during doctor visits.  

“Our goal was to address these barriers by testing a digital program that reaches patients directly, outside of traditional clinical encounters,” said David P. Miller, M.D., professor of implementation science in the Division of Public Health Sciences at Wake Forest University School of Medicine and corresponding author of the study. 

Researchers conducted a randomized clinical trial at two large academic health systems in North Carolina. Over 26,000 individuals with a history of smoking were invited to participate. Those eligible were randomly assigned to either the new digital health program (mPATH-Lung) or to enhanced usual care.  

The enhanced usual care group received a message letting them know they were eligible for lung cancer screening and were encouraged to talk with their primary care doctor about it. They also watched a short video about lung health. This approach provided more information and support than what patients might typically receive but did not include mPATH-Lung. 

The mPATH-Lung program included a brief educational video, a decision aid and the option to request a screening appointment, all delivered online, outside of a clinic visit. The main outcome measured was whether participants completed a chest CT scan for lung cancer screening within 16 weeks. 

Key Findings 

• 24.5% of participants using the digital program completed a screening CT scan, compared to 17% in the usual care group. 

• The program increased screening rates across all demographic and socioeconomic groups. 

• The digital approach allowed patients to learn about screening, weigh the benefits and risks, and easily request appointments. 

• There were no complications from screening-related procedures in either group 

“Our study shows that reaching patients directly with digital tools can help overcome barriers to lung cancer screening and potentially save lives,” Miller said. “By empowering individuals with information and easy access to screening, we can make a real difference in early detection of lung cancer.” 

According to Miller, the findings demonstrate that digital health interventions can modestly but meaningfully increase lung cancer screening rates, even among groups that have historically faced barriers to care. Early detection is crucial, as patients diagnosed at an early stage have much higher survival rates. The study’s approach could be adapted to other preventive health services, helping more people benefit from life-saving screenings. 

The researchers noted that further studies are needed to test digital lung cancer screening programs in a wider range of health care settings and populations. Future research will also explore the best ways to keep patients engaged with digital health tools over time. 

To extend the impact of this work, Miller and co-investigator Ajay Dharod, M.D., associate professor of internal medicine, launched mPATH Health, a startup spun out of Wake Forest University School of Medicine, to make the program widely available and improve lung cancer screening and other preventive care needs. This effort reflects Advocate Health’s academic learning health system model, which emphasizes translating research into real-world solutions that benefit as many people as possible. 

Miller, Dharod and Wake Forest University Health Sciences have ownership interest in the mPATH technology used to conduct this research. 

This research was supported by National Cancer Institute under grant R01CA237240. The project described used the Data and Design Services of the Wake Forest Clinical and Translational Science Institute, which is supported by the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), through award UM1TR004929. Additional funding was provided by the University Cancer Research Fund of the University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center. The project also used services from the North Carolina Translational and Clinical Sciences Institute funded by NCATS through award UM1TR004406. 

Journal

JAMA

Funder

NIH/National Cancer Institute

DOI

10.1001/jama.2025.17281

bu içeriği en az 2000 kelime olacak şekilde ve alt başlıklar ve madde içermiyecek şekilde ünlü bir science magazine için İngilizce olarak yeniden yaz. Teknik açıklamalar içersin ve viral olacak şekilde İngilizce yaz. Haber dışında başka bir şey içermesin. Haber içerisinde en az 12 paragraf ve her bir paragrafta da en az 50 kelime olsun. Cevapta sadece haber olsun. Ayrıca haberi yazdıktan sonra içerikten yararlanarak aşağıdaki başlıkların bilgisi var ise haberin altında doldur. Eğer yoksa bilgisi ilgili kısmı yazma.:
Subject of Research:
Article Title:
News Publication Date:
Web References:
References:
Image Credits:

Keywords

The core innovation lies in the development and application of SnOx nanoflakes synthesized through the electrochemical oxidation of tin disulfide (SnS2) powders. These two-dimensional nanostructures possess exceptional photothermal conversion capabilities, meaning they efficiently absorb near-infrared light and convert it into localized heat. When exposed to LED-generated near-infrared illumination, these nanoflakes become activated, generating enough thermal energy to induce targeted cancer cell death without harming nearby healthy cells. This selectivity is crucial in minimizing collateral damage, a pervasive issue in many current cancer treatments.

Traditional photothermal therapy typically relies on laser sources to direct intense light toward cancerous areas. While effective, lasers are expensive, require specialized and often immobile equipment, and risk damaging surrounding healthy tissues due to their high energy intensity. The substitution of lasers with LEDs in this new approach addresses these limitations directly. LEDs are widely available, cheaper, and can be engineered into compact, portable devices. This transition could democratize access to advanced cancer treatment technologies, especially in underserved regions where hospital-based specialized equipment is scarce.

In vitro experiments have produced compelling evidence supporting the efficacy and safety of this combined LED and SnOx nanoflake therapy. When cultured skin and colorectal cancer cells were exposed to near-infrared LED light in the presence of these nanoflakes, the system achieved up to 92% destruction of skin cancer cells and 50% eradication of colorectal cancer cells within just 30 minutes of treatment. Crucially, these results were obtained without observable detrimental effects on healthy human skin cells, highlighting the treatment’s precision and biocompatibility.

This technology harnesses the principles of near-infrared photothermal therapy, which exploits the tissue-penetrative properties of near-infrared light to deliver heat specifically to malignant cells. As these cancer cells absorb the light-activated heat produced by the SnOx nanoflakes, their local temperature rises to levels sufficient to induce apoptosis or necrosis. Because the therapy operates at relatively low light intensities and employs a biocompatible nanoparticle agent, it promises a gentler alternative to invasive surgical procedures or the systemic toxicity that accompanies many chemotherapeutic regimens.

The successful collaboration between researchers at UT Austin and the University of Porto is bolstered by the UT Austin Portugal Program, a long-standing bilateral scientific partnership bridging U.S. and Portuguese institutions. This program facilitated the transatlantic exchange of expertise, resources, and ideas that enabled the convergence of electrical engineering, materials science, and biomedical research inherent in this project. The synergistic efforts have yielded not only mechanistic insights but also practical prototypes, including custom-designed, near-infrared LED heating systems tailored to activate the SnOx nanoflakes efficiently.

Looking forward, the research team has set ambitious objectives to deepen understanding of the photothermal and photonic interactions governing the therapy’s effectiveness. Further investigation will explore alternative catalytic nanomaterial candidates that may offer enhanced efficacy or novel functional properties. Additionally, device engineering is a critical next step, focusing on developing user-friendly, portable platforms capable of delivering this therapy in clinical and even home-based settings, particularly for skin cancer patients.

One envisioned application is a wearable, lightweight device that a patient could place directly on the skin post-surgery to irradiate the surgical site and eradicate residual cancerous cells. Such an approach could significantly reduce recurrence rates and alleviate patients from repeated hospital visits. Moreover, the anticipated low-cost nature of the technology could facilitate adoption in low-resource environments worldwide, addressing long-standing disparities in cancer treatment accessibility.

The therapeutic use of SnOx nanoflakes also exemplifies the frontier of two-dimensional material science in biomedical applications. The nanoscale morphology and high surface area of these flakes enhance their interaction with near-infrared light and maximize thermal conversion. This precision targeting at the cellular level optimizes therapeutic outcomes while minimizing systemic side effects. The team continues to optimize the synthesis and functionalization of these nanomaterials, tailoring their physicochemical properties to improve stability, biocompatibility, and treatment efficacy.

An additional exciting outcome of this multidisciplinary venture is the recent procurement of supplementary funding aimed at developing an implantable device for breast cancer patients. This implant would integrate the photothermal capabilities of SnOx nanoflakes with minimally invasive delivery methods, representing an advanced step in personalized cancer therapy. It underscores the broad potential of this research beyond topical or external applications, opening avenues for treatment of diverse cancer types.

Besides the principal investigators, the research effort encompasses a diverse team of scientists and engineers. Their collective expertise spans electrical engineering, nanomaterial synthesis, biological characterization, and device engineering, epitomizing a modern collaborative approach to translational research. Notably, the development of the LED systems was spearheaded by contributors from the University of Trás-os-Montes and Alto Douro, showcasing a wide-reaching network of academic partnerships within Portugal.

This novel therapeutic approach is a landmark in photothermal cancer therapies, promising to surmount critical barriers hampering previous iterations of the technology. By leveraging more affordable and accessible LED technology alongside advanced nanomaterials, the method holds promise not only for improving patient outcomes but also for fundamentally reshaping cancer treatment modalities worldwide. Its evolution from laboratory discovery through clinical device development may transform how cancer is managed globally, combining cutting-edge science with practical healthcare delivery.

The fusion of material science, optical engineering, and oncology demonstrated in this work exemplifies the forward trajectory of cancer research. As this method progresses towards clinical trials and broader implementation, the scientific and medical communities will be closely watching its impact. With continued innovation, this LED-activated SnOx nanoflake therapy could inaugurate a new era of cancer treatment—one defined by precision, safety, accessibility, and hope for millions of patients worldwide.

Subject of Research: Cancer treatment using near-infrared photothermal therapy with SnOx nanoflakes activated by LED light.

Article Title: SnOx Nanoflakes as Enhanced Near-Infrared Photothermal Therapy Agents Synthesized from Electrochemically Oxidized SnS2 Powders

Web References:
https://doi.org/10.1021/acsnano.5c03135

References: ACS Nano, peer-reviewed journal article reporting experimental results and material synthesis details.

Image Credits: The University of Texas at Austin

Keywords: cancer, skin cancer, colorectal cancer, cancer cells, cancer research, cancer treatments

The new technology, GoT-Multi, is a formidable leap beyond its predecessor, enabling the simultaneous detection of numerous gene mutations while also monitoring the transcriptomic activity within the same individual cells. By overcoming prior limitations—most notably the inability to analyze formalin-fixed, paraffin-embedded (FFPE) pathology samples—GoT-Multi vastly expands the scope of cancer specimens accessible for in-depth study. These FFPE samples constitute an immense archive in clinical pathology departments worldwide, encapsulating invaluable clinical history that has largely been inaccessible with single-cell multi-omics methods until now.

The significance of GoT-Multi was powerfully illustrated through its application to chronic lymphocytic leukemia (CLL), a typically indolent blood cancer that can undergo a dramatic and often fatal transformation into a highly aggressive lymphoma subtype, known as Richter Transformation. The research team applied GoT-Multi to tens of thousands of individual malignant cells from patient tissue samples, identifying more than two dozen specific gene mutations within single cells and concurrently mapping their gene expression profiles. This dual-layered approach provided a comprehensive view of how mutational changes intersect with cellular behaviors—such as proliferative activity and inflammatory responses—during malignant progression.

This capability to dissect tumor heterogeneity at an extraordinary resolution unveils the dynamic cellular states within evolving cancers. Cells exhibiting hyperproliferation or inflammatory phenotypes were readily classified and correlated to their genetic alterations, revealing pathways involved in treatment resistance and aggressiveness. The implications of understanding these cellular subpopulations are profound, offering potential biomarkers for early detection of transformation events and rational targets for therapeutic intervention that precisely address the malignant subclones resistant to conventional therapies.

The development of GoT-Multi was spearheaded by Dr. Anna Nam, whose leadership in pathology and laboratory medicine has established her as a key figure in precision oncology. The tool’s conceptual and technical foundations originated during her postdoctoral tenure under Dr. Dan Landau at Weill Cornell Medicine, a noted expert in cancer genomics. Together, they laid the groundwork for single-cell genotyping integrated with transcriptomics, setting a foundation that GoT-Multi has robustly expanded upon with enhanced mutation detection capacity and sample versatility.

A defining technical advancement of GoT-Multi lies in its multiplexing capacity—allowing researchers to concurrently genotype multiple loci across the genome while capturing the cell’s transcriptomic profile. This multi-omics integration eliminates the need for separate assays, reducing variability and preserving the integrity of biological signals inherent to each cell. The system leverages state-of-the-art sequencing technologies and computational frameworks to accurately phase mutations and interrogate gene expression patterns linked to neoplastic progression and therapeutic escape.

The research consortium’s decision to focus initially on hematologic malignancies, particularly treatment-resistant lymphomas, represents a strategic choice reflecting the urgent clinical need to understand and counteract therapy failure. By applying GoT-Multi to large cohorts of lymphoma biopsies, they aim to systematically profile the cellular ecosystem underlying resistance, potentially uncovering conserved molecular pathways that can be exploited to design next-generation targeted therapies. These investigations also extend to precancerous states, providing a continuum view from early neoplastic lesions through to fully transformed and resistant tumors.

Beyond its scientific and clinical implications, GoT-Multi underscores the power of integrating advanced technological innovation with rich clinical samples to push the boundaries of cancer biology. The ability to study archival FFPE specimens opens vast retrospective research possibilities, linking genetic and transcriptomic alterations to long-term patient outcomes and therapeutic histories. Consequently, this technology offers a transformative platform for longitudinal studies and real-world data integration that were previously unfeasible.

Importantly, the cross-institutional collaboration between Weill Cornell Medicine and the University of Adelaide exemplifies the global synergies necessary for tackling complex biomedical challenges. The synthesis of expertise spanning pathology, molecular biology, oncology, and bioinformatics has yielded a robust tool that not only enhances our mechanistic understanding of cancer transformation but also serves as a beacon for the future of personalized medicine.

The GoT-Multi platform is poised to catalyze a new era of precision diagnostics, providing clinicians with granular insights into tumor evolution and empowering them to tailor interventions based on the unique mutational and transcriptional landscape of a patient’s cancer. As the field moves toward integrating single-cell multi-omics into routine clinical workflows, the translation of these insights holds the promise of improved prognostication, more effective therapies, and ultimately, better patient outcomes.

Looking forward, the research team is expanding the scope of their investigations, applying GoT-Multi across diverse tumor types and exploring its utility beyond oncology, such as in autoimmune diseases and developmental disorders. The adaptability of the platform to various tissue preparations and its scalability positions it as a versatile tool for broad biological and clinical research applications.

In conclusion, GoT-Multi represents a formidable advance in cancer genomics, uniting genotyping and transcriptomics in a single, scalable assay compatible with real-world clinical samples. By illuminating the molecular intricacies of cancer progression and drug resistance at the single-cell level, this technology sets the stage for transformative discoveries and fosters a new paradigm in precision oncology research and patient care.

Subject of Research: Genotyping and transcriptomic profiling of cancer cells using single-cell multi-omics technology to investigate cancer progression and treatment resistance.

Article Title: Cancer Progression Illuminated by New Multi-Omics Tool

News Publication Date: 10-Oct-2025

Image Credits: Courtesy of the Nam Lab

Keywords: Pathology, Cell pathology

Osteosarcoma represents the most common type of malignant bone tumor in the pediatric population, primarily arising in the long bones of the limbs, such as the arms and legs. Despite advances in oncology, treatment outcomes for osteosarcoma have stagnated over the last four decades, underscoring the urgent need for novel insights into its pathogenesis and potential therapeutic targets. The devastating nature of this cancer is highlighted by its survival rates: approximately 70% of patients survive if the disease remains localized, but this plummets to roughly 20% when metastasis occurs.

This study harnessed the power of large-scale genetic data by analyzing genomic information from nearly 6,000 pediatric cancer patients and contrasting it with data collected from over 14,000 adult controls devoid of cancer diagnoses. The researchers specifically examined mutations in 189 genes implicated in various DNA repair pathways—a biological system critical to the maintenance of genomic integrity. DNA repair mechanisms correct damage inflicted on DNA, which if left unresolved, can initiate mutagenic processes leading to cancerous growth.

The crux of the findings lies in the identification of inherited mutations in the SMARCAL1 gene as a noteworthy risk factor in osteosarcoma development. SMARCAL1 encodes an ATP-dependent DNA annealing helicase that plays an essential role in replication fork stabilization and repair of DNA double-strand breaks, key aspects of maintaining genomic stability during cell division. Mutations in SMARCAL1 are hypothesized to disrupt normal DNA repair capacity, allowing for the accumulation of genetic aberrations that drive oncogenesis in bone tissue.

Approximately 2.6% of children diagnosed with osteosarcoma were found to carry these inherited mutations in SMARCAL1, suggesting a significant genetic predisposition that had previously gone unrecognized. This not only advances our understanding of osteosarcoma’s molecular underpinnings but also opens avenues for genetic screening programs designed to identify at-risk populations early, allowing for preemptive monitoring or intervention.

Such insights into DNA repair dysfunction further illuminate the broader relationship between genomic instability and pediatric cancer susceptibility. DNA damage response (DDR) genes, integral to detecting and repairing lesions, are increasingly recognized as central to the vulnerability of cells to malignant transformation. The study’s focus on 189 DNA repair-associated genes underscores a systemic approach to deciphering genetic predispositions, moving beyond single gene mutations to a network of interrelated genomic maintenance pathways.

The implications for clinical practice are profound. Identification of SMARCAL1 mutations as a marker for osteosarcoma risk sharpens the potential for personalized medicine strategies. Therapies targeting DNA repair pathways, including synthetic lethality approaches or agents that induce DNA damage selectively in cancer cells, could be tailored based on an individual’s genetic profile. Moreover, earlier diagnosis through genetic risk assessment may enhance patient outcomes by initiating treatment before metastasis sets in.

Dr. Richa Sharma, a pediatric hematologist and oncologist at Cleveland Clinic Children’s and the study’s senior author, emphasized that these findings represent a transformative stride in the fight against an aggressive and rare malignancy. Given the minimal progress in osteosarcoma treatment protocols over the last 40 years, understanding the biological basis of the disease at the genetic level is pivotal to developing innovative therapies and improving survival rates.

The research methodology was robust, integrating next-generation sequencing technologies with comprehensive bioinformatic analyses, thus offering an unprecedented depth of insight into the genomic landscapes of pediatric cancers. By comparing cancer-afflicted children to a large cohort of cancer-free adults, the researchers effectively delineated inherited mutational burdens that predispose to malignancy, ruling out sporadic mutations associated with tumorigenesis.

Furthermore, this work reinforces the critical importance of collaborative, multi-institutional studies in rare pediatric cancers. By pooling genetic data across continents and institutions, the scientific community amplifies its capabilities to detect subtle, yet clinically significant, genetic variants that single-center studies might overlook.

Despite the breakthrough, experts caution that SMARCAL1 mutations represent one piece within a complex puzzle of osteosarcoma etiology. Environmental factors, other genetic alterations, and epigenetic modifications also likely contribute to tumor development. Continuous research will be essential to fully elucidate these mechanisms and translate them into reliable diagnostic and treatment paradigms.

In summary, this landmark investigation validates the hypothesis that defects in DNA damage response genes are integral to pediatric cancer risk and establishes SMARCAL1 as a novel osteosarcoma predisposition gene. This breakthrough advances not only the scientific community’s understanding of osteosarcoma’s molecular basis but also offers hope for future innovations in detection, prevention, and targeted therapy of this devastating pediatric cancer.

Subject of Research: Osteosarcoma, pediatric bone cancer, DNA repair genes, genetic predisposition

Article Title: Investigation of DNA damage response genes validates the role of DNA repair in pediatric cancer risk and identifies SMARCAL1 as novel osteosarcoma predisposition gene

News Publication Date: October 8, 2025

Web References:

• Journal of Clinical Oncology: https://ascopubs.org/toc/jco/0/ja
• DOI link: http://dx.doi.org/10.1200/JCO-25-01114

Keywords:
Osteosarcoma, pediatric cancer, bone cancer, DNA repair, molecular genetics, cancer predisposition, SMARCAL1, DNA damage response, genetic risk factors, pediatric oncology, genomic instability, targeted therapy

In metastasis, genetics meet geography, study finds

Mutations that drive the growth and survival of cancer cells can help a primary tumor spread to new sites, but the extent to which they help sustain tumor growth at these metastatic sites has been unclear.

An MSK-led research team — led by first author Kaloyan Tsanov, PhD, a former postdoc at MSK who now heads his own lab at the University of Chicago — looked for answers using one such gene, SMAD4, which is commonly inactivated by mutations in gastrointestinal cancers.

The scientists used a mouse model of pancreatic cancer to study whether metastatic tumors remain dependent on SMAD4 deactivation by turning off the gene in early tumor development and later reactivating it in established metastases. Interestingly, they found reactivating SMAD4 had different effects based on the location of the metastasis. It suppressed liver metastases but encouraged the expansion of lung metastases.

“We found that different organ sites select for different cell types present in the primary tumor, and that this can dramatically alter what they need to remain viable,” says senior study author Scott Lowe, PhD, Chair of the Cancer Biology and Genetics Program at MSK’s Sloan Kettering Institute.

“The broader implication is that the effectiveness of some therapies may not only be related to the gene mutations in the tumors, but also where in the body these tumor cells reside,” Dr. Tsanov adds. Read more in Nature Cancer. 

How regulatory T cells work with sensory nerves in the skin to restrain pain and inflammation

Nerve endings in our skin help protect us by sensing a variety of stimuli, including extreme temperature, physical forces, tissue damage, and infection — and by generating sensations like itching or pain. But a growing body of work suggests that these neuronal cells also help mobilize an immune response when confronted with threats.

New MSK research — led by Alejandra Mendoza, PhD, a postdoc in the lab of senior study author Alexander Rudensky, PhD, at the Sloan Kettering Institute — examined the relationship between regulatory T cells (Tregs) and these peripheral neurons. (Dr. Mendoza is now an assistant professor of immunology and microbiology at Scripps Research.)

Tregs are key immune cells that promote tolerance to “self” and to helpful bacteria, harmless food allergens, and long-term infections. Using mouse models of psoriasis-like inflammation, the research team determined that Tregs play an important role in limiting overactivation of sensory neurons in the skin — thereby limiting inflammation — at the early stages of an infection. The researchers also found that Treg expression of Penk — a gene that encodes a neuropeptide called enkephalin, which produces an analgesic effect — is essential to Treg cells’ ability to help regulate the body’s response to pain.

Overall, the study suggests that Tregs, by acting as a part of a mixed immune cell-neuronal circuit, play a vital role in keeping the body from excessive responses when the skin encounters a new threat. Read more in Science Immunology. (The study was also highlighted in the ScienceAdviser newsletter.)

Studying whether a large language model can adequately summarize cancer patients’ experiences with pain

Patient-reported outcomes (PROs) have become a critical component of clinical research to assess the benefits of new medical therapies, including treatments for cancer. These outcomes include factors that affect a patient’s quality of life, such as fatigue, mood, and pain. PROs are generally collected by asking patients to fill out questionnaires, but researchers, including those at MSK, are studying whether large language models like ChatGPT could help to capture PROs in a patient’s own words.

As part of that effort, an MSK team co-led by outcomes research scientist Talya Salz, PhD, and behavioral scientist Thomas Atkinson, PhD, recently received a grant from the nonprofit Patient-Centered Outcomes Research Institute (PCORI) to study how an algorithm guided by a large language model could help identify themes related to the experience of cancer pain from narrative reports. Using the model, named PainReporter, the team will evaluate the extent to which the themes identified by the model agree with conventional PROs metrics of pain. They will also evaluate how patients perceive the accuracy the PainReporter summary and their experiences using the model. Learn more about this project on the PCORI website.

Proton therapy effective at treating leptomeningeal metastasis

Leptomeningeal metastasis (LM) is a serious condition in which cancer spreads to the fluid and tissues surrounding the brain and spinal cord. New results from a randomized phase 2 clinical trial at MSK show that craniospinal proton therapy, an advanced form of radiation therapy, is effective in controlling LM.

In LM patients who received proton therapy to the brain and spinal cord (also called proton craniospinal irradiation), the disease remained stable more than three times longer than in those who got conventional radiation to just the brain or portions of the spinal cord. Patients receiving proton craniospinal therapy also lived more than twice as long.

Earlier results were presented in 2022 at the annual meeting of the American Society of Clinical Oncology (ASCO) by Jonathan Yang, MD, PhD, who has since left MSK. Dr. Yang collaborated closely with neuro-oncologist Adrienne Boire, MD, PhD, who has devoted her research to finding additional ways to block LM.

“This work shows that it is essential to treat both the brain and the spinal cord when treating LM. It’s very exciting that we have an effective new option for a disease that is very hard to treat,” Dr. Boire says. “Previous radiation techniques did not allow us to treat the brain and spinal cord. These results show that proton therapy should be considered when it is available.” Read more in JAMA Oncology.

            Media Contact



                                Nick Gardner

                Memorial Sloan Kettering Cancer Center


            gardnern@mskcc.org


                Office: 917-843-3834










            Keywords




                          /Scientific community/Research programs/Cancer research




                              /Scientific community/Scientific approaches/Basic research




                               /Scientific community/Scientific approaches/Discovery research




                               /Scientific community/Research programs/Clinical research




                               /Health and medicine/Diseases and disorders/Cancer/Metastasis




         bu içeriği en az 2000 kelime olacak şekilde ve alt başlıklar ve madde içermiyecek şekilde ünlü bir science magazine için İngilizce olarak yeniden yaz. Teknik açıklamalar içersin ve viral olacak şekilde İngilizce yaz. Haber dışında başka bir şey içermesin. Haber içerisinde en az 12 paragraf ve her bir paragrafta da en az 50 kelime olsun.  Cevapta sadece haber olsun. Ayrıca haberi yazdıktan sonra içerikten yararlanarak aşağıdaki başlıkların bilgisi var ise haberin altında doldur. Eğer yoksa bilgisi ilgili kısmı yazma.: 

Subject of Research:
Article Title:
News Publication Date:
Web References:
References:
Image Credits:

Keywords

A groundbreaking study led by the Berman Lab at the CHEO Research Institute and the University of Ottawa, in close collaboration with national precision oncology networks across Canada and Australia, has demonstrated the power of pre-clinical zebrafish models in real-time clinical decision-making. This research marks a pivotal step forward by establishing that larval zebrafish patient-derived xenograft (PDX) models can reliably replicate and predict drug responses observed in actual pediatric cancer patients. Unlike traditional mouse models, which have dominated the pre-clinical landscape, zebrafish offer unparalleled speed, cost-effectiveness, and sensitivity that could revolutionize precision pediatric oncology.

Dr. Jason Berman, pediatric oncologist and CEO of CHEO Research Institute, underscores the personal impact of this innovation. “When delivering difficult news to families, having the ability to offer hope based on a concrete understanding of how a child might respond to treatment is invaluable,” he explains. Zebrafish offer that window into personalized therapy, illuminating effective drug regimens well ahead of conventional models. Their unique biology—small size, rapid development, and optical transparency—enables researchers to graft human tumor tissues and observe therapeutic effects in a live organism within days, vastly accelerating the treatment selection process.

In terms of technical specifics, the larval zebrafish PDX approach involves transplanting tumor cells derived from pediatric patients directly into transparent larvae. These xenografts allow for direct observation of tumor drug responses in real-time, facilitating precise evaluation of efficacy and resistance patterns. This approach is particularly advantageous in pediatric oncology, where sample sizes from biopsies are limited, and treatment windows are narrow. Zebrafish models require only minute quantities of tumor tissue, a remarkable advantage over mouse models that often demand larger samples and longer engraftment periods.

The study published in Cancer Research Communications represents the first direct comparison between zebrafish PDX models, traditional mouse PDX models, and actual patient clinical outcomes. By retrospectively analyzing samples from ten children enrolled in the Zero Childhood Cancer program in Australia, researchers were able to assess the fidelity of zebrafish drug response patterns against the backdrop of real-world therapeutic results. Remarkably, the zebrafish PDX models predicted responses accurately in 11 out of 12 treatment regimens, surpassing mouse models in terms of speed and, in several cases, feasibility.

Significantly, for three of the high-risk patients whose tumor tissues failed to establish viable mouse PDX models, zebrafish larvae successfully generated robust drug response data. This finding highlights the zebrafish model’s superior adaptability and its potential to fill critical gaps in pediatric cancer research, especially for aggressive cancers where time-sensitive treatment decisions are paramount. By delivering reliable predictions in a fraction of the time, zebrafish models could effectively serve as frontline bioassays guiding personalized therapies in clinical settings.

The implications of this study stretch beyond model validation, touching on the broader paradigm of precision medicine for childhood cancers. Dr. David Malkin, co-chair of ACCESS and senior staff oncologist at SickKids, elaborates on this bridge between bench and bedside. “Precision tumor modeling with zebrafish is not merely an experimental tool; it’s a transformative clinical instrument that ensures children receive not just care, but the right care, tuned finely to their cancer’s unique biology.” Such advances are crucial because even with extensive genomic sequencing, many pediatric cancers remain without identifiable druggable mutations, leaving clinicians with few targeted treatment strategies.

Technically and ethically, zebrafish offer additional advantages that augment their value in preclinical oncology. Their rapid breeding cycles and transparent embryos permit high-throughput drug screening while minimizing ethical concerns associated with mammalian testing. The external development of embryos allows continuous real-time visualization without invasive procedures, providing unparalleled access to tumor microenvironment dynamics and drug interactions within the living organism. This system empowers researchers to iterate therapeutic testing quickly and identify promising drug candidates or combinations before advancing to more resource-intensive mammalian models or clinical trials.

Another key dimension of this research is its alignment with international collaborative networks such as Canada’s PROFYLE and Australia’s ZERO programs. These networks emphasize molecular profiling and precision medicine tailored to children and young adults with cancer, leveraging multi-institutional expertise and data-sharing. The integration of zebrafish PDX modeling with extensive genomic analyses promises a holistic approach, combining molecular insights with functional testing to optimize treatment plans. This convergence of technologies accelerates personalized therapy pipelines with the overarching goal of improving survival and quality of life for patients facing otherwise grim prognoses.

Importantly, co-senior author Dr. Michelle Haber from the Children’s Cancer Institute in Sydney highlights the clinical utility of zebrafish PDX modeling in cases where molecular profiling alone falls short. She points out that when actionable genomic targets cannot be identified, observing how patient-derived tumors respond dynamically to available drugs in zebrafish becomes a valuable alternative to guide therapeutic decisions. This innovation enhances the traditional precision medicine toolkit, ensuring more children receive hope and tailored care even in challenging diagnostic scenarios.

Beyond treatment selection, this study sets the stage for future prospective use of zebrafish models in clinical oncology. By embedding functional assays within clinical workflows, physicians could potentially receive timely, empirically supported guidance to adjust therapeutic regimens on the fly, responding to tumor evolutions and resistance mechanisms as they arise. The rapid turnaround offered by zebrafish PDX allows for such nimble clinical adaptations, potentially reducing trial-and-error approaches and sparing patients from ineffective treatments and attendant toxicities.

As the landscape of pediatric cancer therapy evolves, the promise of zebrafish models encapsulates a broader shift toward adaptive, precise, and patient-centered oncology. This model system’s success illustrates an elegant marriage of basic science and translational medicine, where organismal biology informs human healthcare. Energetic ongoing collaborations across borders exemplify the commitment to leverage these insights for tangible patient benefit, accelerating not just the pace of research but the very hope entrusted to families confronting pediatric cancer.

In sum, the zebrafish larval PDX model heralds a transformative advance in pediatric cancer precision therapy. Through its rapid, accurate, and scalable drug response profiling, it addresses crucial limitations of existing preclinical models, enabling clinicians to craft personalized therapeutic strategies with greater confidence and speed. The impact of this innovation will ripple through research, clinical protocols, and ultimately patient outcomes—offering a beacon of hope for children with some of the most aggressive and difficult-to-treat cancers.

Subject of Research: Human tissue samples

Article Title: Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy

News Publication Date: 25-Jul-2025

Web References:

• CHEO Research Institute: https://www.cheoresearch.ca/
• ACCESS: https://www.accessforkidscancer.ca/
• PROFYLE: https://www.profyle.ca/
• ZERO: https://www.zerochildhoodcancer.org.au/
• Children’s Cancer Institute: http://ccia.org.au

References:
Azzam, N., Fletcher, J. I., Melong, N., Lau, L. M. S., Dolman, E. M., Mao, J., Tax, G., Cadiz, R., Tuzi, L., Kamili, A., Dumevska, B., Xie, J., Chan, J. A., Senger, D. L., Grover, S. A., Malkin, D., Haber, M., & Berman, J. N. (2025). Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy. Cancer Research Communications, 5(7), 1215–1227. DOI: 10.1158/2767-9764.CRC-25-0080

Image Credits: CHEO

Immunotherapy has transformed cancer treatment by harnessing the power of the immune system, specifically T cells, to attack malignant cells. However, despite remarkable successes in some patients, many do not respond or eventually develop resistance. The recently published study in Theranostics explores one underappreciated culprit behind this resistance: a circulating form of Clever-1 protein that dampens the immune response on a systemic level. This secreted protein disables T cell activation, making tumors invisible to one of the body’s primary defense mechanisms.

Clever-1, previously identified as a receptor on certain immune cells like macrophages, plays a suppressive role within the tumor microenvironment. The novel discovery focuses on sClever-1, which is released into the bloodstream and exerts a far-reaching inhibitory effect on T cells. By binding directly to activated T cells, sClever-1 disrupts their ability to signal and coordinate an effective anti-tumor immune response. This molecular “cloak” aids cancer cells in evading destruction, helping to explain why some tumors remain impervious to current immunotherapies like anti-PD-1 antibodies.

The study’s lead co-author, Professor Shishir Shetty of the University of Birmingham, emphasized the clinical relevance of these findings. He explained that elevated levels of sClever-1 in patients’ blood correlate strongly with resistance to established immunotherapeutic agents. This protein thus serves as both a biomarker for predicting treatment outcomes and a therapeutic target. The investigational antibody bexmarilimab was shown to inhibit the release of sClever-1, effectively lifting the immunosuppressive blockade and restoring T cell function.

Bexmarilimab represents a promising new class of drugs that not only counteract suppressive signals but also reprogram tumor-associated macrophages to support immune activation rather than inhibition. This dual functionality—blocking sClever-1 secretion and revitalizing immune cells—marks a significant advance in combination therapy approaches. Professor Shetty highlighted the potential to identify patients unlikely to benefit from monotherapy immunotherapies and instead offer tailored regimens incorporating bexmarilimab.

The international collaboration drew upon advanced immunological techniques, including plasma analysis from a robust cohort of patients encompassing 138 breast cancer cases, 193 individuals with advanced solid tumours, and 21 healthy donors. This comprehensive comparative analysis revealed markedly higher concentrations of sClever-1 in cancer patients’ circulation, underpinning its role as a systemic modulator of immunity rather than a localized factor confined to the tumor microenvironment.

Dr. Maija Hollmén, senior author from the University of Turku and the InFLAMES Flagship program, reflected on the broader implications of these mechanistic insights. By uncovering how cancer manipulates immune checkpoints at a molecular level through sClever-1 secretion, the research clarifies a key immune evasion strategy. This knowledge not only validates bexmarilimab’s molecular target but also encourages the development of novel agents capable of dismantling similar suppressive pathways.

A particularly striking aspect of the research is the demonstration that inflammatory signals within the tumor microenvironment induce macrophages and other immune cells to release sClever-1. This discovery links the inflammatory milieu of tumors to systemic immunosuppression and provides a mechanistic framework explaining why some tumors are refractory to PD-1 checkpoint inhibitors. It underscores the complexity of immune regulation in cancer and the need for multi-targeted treatment regimens.

The novel recognition that circulating sClever-1 directly binds to activated T cells advances our fundamental understanding of immune biology in cancer. T cells are central to orchestrating cytotoxic responses, and their functional paralysis by sClever-1 represents a critical barrier to effective immunotherapy. This paradigm shifts the focus from solely targeting checkpoints on T cells to also modulating systemic factors that govern T cell competence.

As immunotherapy continues to evolve, these findings highlight the necessity of personalized medicine strategies that incorporate molecular biomarkers like sClever-1. The ability to stratify patients based on their sClever-1 levels could refine treatment decisions, selecting candidates who would benefit from bexmarilimab-inclusive combinations. This precision approach aims to overcome the heterogeneity and complexity of tumor-immune interactions that limit current therapeutic efficacy.

The study’s forthcoming presentation at the 19th International Congress of Immunology (IUIS 2025) promises to ignite widespread interest and foster collaborative efforts to translate these insights into clinical practice. Supported by Faron Pharmaceuticals, which is developing bexmarilimab, the research epitomizes the synergy between academia and industry in accelerating innovation against cancer.

In summary, the identification and characterization of secreted Clever-1 as a systemic immune suppressor heralds a watershed moment in cancer immunotherapy research. By unveiling how sClever-1 impairs T cell activation and contributes to resistance against widely used treatments, the study opens new therapeutic avenues. The investigational antibody bexmarilimab’s capacity to inhibit this suppressive pathway and restore immune function offers hope for improving outcomes in patients with advanced, treatment-resistant cancers.

This pivotal work not only showcases the power of cutting-edge molecular and immunological techniques but also exemplifies the importance of global scientific collaboration. As the fight against cancer intensifies, such detailed mechanistic understanding will be indispensable for designing smarter, more efficacious immunotherapies. With further clinical validation, targeting sClever-1 could become a cornerstone in overcoming the immunotherapy resistance that currently curtails patient survival.

Subject of Research: The role of secreted Clever-1 (sClever-1) in modulating T cell responses and its impact on the efficacy of cancer immunotherapy.

Article Title: Secreted Clever-1 modulates T cell responses and impacts cancer immunotherapy efficacy

News Publication Date: 23-Jun-2025

Web References:

• https://www.thno.org/v15p7501.htm
• http://dx.doi.org/10.7150/thno.110544

References:
DOI: 10.7150/thno.110544

Keywords:
Immunotherapy, Immunology, Immunological techniques, Cancer